Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis
Purpose To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[ 18 F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH). Methods Twenty-three children with LCH underwent 2-[ 18 F]FDG PET and WB DW-MRI at baseline. Two nuclear me...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2023-05, Vol.50 (6), p.1689-1698 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1698 |
---|---|
container_issue | 6 |
container_start_page | 1689 |
container_title | European journal of nuclear medicine and molecular imaging |
container_volume | 50 |
creator | Baratto, Lucia Nyalakonda, Ramyashree Theruvath, Ashok J. Sarrami, Amir Hossein Hawk, Kristina Elizabeth Rashidi, Ali Shen, Sa States, Lisa Aboian, Mariam Jeng, Michael Daldrup-Link, Heike E. |
description | Purpose
To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[
18
F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH).
Methods
Twenty-three children with LCH underwent 2-[
18
F]FDG PET and WB DW-MRI at baseline. Two nuclear medicine physicians and two radiologists independently assessed presence/absence of tumors in 8 anatomical areas. Sixteen children also performed 2-[
18
F]FDG PET and WB DW-MRI at follow-up. One radiologist and one nuclear medicine physician revised follow-up scans and collected changes in tumor apparent diffusion (ADC) and standardized uptake values (SUV) before and after therapy in all detectable lesions. 2-[
18
F]FDG PET results were considered the standard of reference for tumor detection and evaluation of treatment response according to Lugano criteria. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of WB DW-MRI at baseline were calculated, and the 95% confidence intervals were estimated by using the Clopper-Pearson (exact) method; changes in tumor SUVs and ADC were compared using a Mann–Whitney
U
test. Agreement between reviewers was assessed with a Cohen’s weighted kappa coefficient. Analyses were conducted using SAS software version 9.4.
Results
Agreement between reviewers was perfect (kappa coefficient = 1) for all analyzed regions but spine and neck (kappa coefficient = 0.89 and 0.83, respectively) for 2-[
18
F]FDG PET images, and abdomen and pelvis (kappa coefficient = 0.65 and 0.88, respectively) for WB DW-MRI. Sensitivity and specificity were 95.5% and 100% for WB DW-MRI compared to 2-[
18
F]FDG PET. Pre to post-treatment changes in SUV
ratio
and ADC
mean
were inversely correlated for all lesions (
r
: -0.27,
p
= 0·06) and significantly different between responders and non-responders to chemotherapy (
p
= 0.0006 and
p
= 0·003 for SUV
ratio
and ADC
mean
, respectively).
Conclusion
Our study showed that WB DW-MRI has similar accuracy to 2-[
18
F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[
18
F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone. |
doi_str_mv | 10.1007/s00259-023-06122-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10121877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2771334187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-f3d7aa108e0ee39c084daf3ac3398302373169b876662a207fc116f675a5c5ca3</originalsourceid><addsrcrecordid>eNp9kc9uEzEQxlcIREvhBTggS1y4GMb2xvaeEEqbtlIQCBVxQMhyvN6sq107tR2qPAGvXYct4c-B01ia33wzn7-qek7gNQEQbxIAnTUYKMPACaWYP6iOCScNFiCbh4e3gKPqSUrXAERS2TyujhgXRNTQHFc_5mHc6OhS8Ch06LYPg8Wr0O7Q6Rf8_tMlunW5RxR_JXLxbXF6jj6eXaEuRJSyXju_Rtq3KEer82h9RmPwLoe4bxQ107uhjdZPIkvt1zb22idk7DCg3qXsgtnlkFx6Wj3q9JDss_t6Un1enF3NL_Dyw_nl_N0Sm5qRjDvWCq0JSAvWssaArFvdMW0YayQrPyEY4c1KCs451RREZwjhHRczPTMzo9lJ9XbS3WxXo21NOTrqQW2iG3XcqaCd-rvjXa_W4bsiQCiRQhSFV_cKMdxsbcpqdGlvSHsbtklRIQhjdWEL-vIf9Dpsoy_-FJXAuOSsZoWiE2ViSCna7nANAbUPWk1Bq2JP_Qxa8TL04k8fh5FfyRaATUDa7OOw8ffu_8jeAQJ7tA8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803686343</pqid></control><display><type>article</type><title>Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Baratto, Lucia ; Nyalakonda, Ramyashree ; Theruvath, Ashok J. ; Sarrami, Amir Hossein ; Hawk, Kristina Elizabeth ; Rashidi, Ali ; Shen, Sa ; States, Lisa ; Aboian, Mariam ; Jeng, Michael ; Daldrup-Link, Heike E.</creator><creatorcontrib>Baratto, Lucia ; Nyalakonda, Ramyashree ; Theruvath, Ashok J. ; Sarrami, Amir Hossein ; Hawk, Kristina Elizabeth ; Rashidi, Ali ; Shen, Sa ; States, Lisa ; Aboian, Mariam ; Jeng, Michael ; Daldrup-Link, Heike E.</creatorcontrib><description>Purpose
To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[
18
F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH).
Methods
Twenty-three children with LCH underwent 2-[
18
F]FDG PET and WB DW-MRI at baseline. Two nuclear medicine physicians and two radiologists independently assessed presence/absence of tumors in 8 anatomical areas. Sixteen children also performed 2-[
18
F]FDG PET and WB DW-MRI at follow-up. One radiologist and one nuclear medicine physician revised follow-up scans and collected changes in tumor apparent diffusion (ADC) and standardized uptake values (SUV) before and after therapy in all detectable lesions. 2-[
18
F]FDG PET results were considered the standard of reference for tumor detection and evaluation of treatment response according to Lugano criteria. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of WB DW-MRI at baseline were calculated, and the 95% confidence intervals were estimated by using the Clopper-Pearson (exact) method; changes in tumor SUVs and ADC were compared using a Mann–Whitney
U
test. Agreement between reviewers was assessed with a Cohen’s weighted kappa coefficient. Analyses were conducted using SAS software version 9.4.
Results
Agreement between reviewers was perfect (kappa coefficient = 1) for all analyzed regions but spine and neck (kappa coefficient = 0.89 and 0.83, respectively) for 2-[
18
F]FDG PET images, and abdomen and pelvis (kappa coefficient = 0.65 and 0.88, respectively) for WB DW-MRI. Sensitivity and specificity were 95.5% and 100% for WB DW-MRI compared to 2-[
18
F]FDG PET. Pre to post-treatment changes in SUV
ratio
and ADC
mean
were inversely correlated for all lesions (
r
: -0.27,
p
= 0·06) and significantly different between responders and non-responders to chemotherapy (
p
= 0.0006 and
p
= 0·003 for SUV
ratio
and ADC
mean
, respectively).
Conclusion
Our study showed that WB DW-MRI has similar accuracy to 2-[
18
F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[
18
F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-023-06122-6</identifier><identifier>PMID: 36717409</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Accuracy ; Autoimmune diseases ; Cardiology ; Chemotherapy ; Child ; Children ; Coefficients ; Diffusion Magnetic Resonance Imaging - methods ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Health services ; Histiocytosis ; Histiocytosis, Langerhans-Cell - diagnostic imaging ; Histiocytosis, Langerhans-Cell - therapy ; Humans ; Imaging ; Kappa coefficient ; Langerhans cell histiocytosis ; Lesions ; Magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Medicine ; Medicine & Public Health ; Monitoring ; Neoplasm Staging ; Neoplasms ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Pelvis ; Physicians ; Positron emission ; Positron emission tomography ; Positron-Emission Tomography - methods ; Radiation effects ; Radiology ; Radiopharmaceuticals ; Telemedicine ; Tumors ; Whole Body Imaging - methods</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2023-05, Vol.50 (6), p.1689-1698</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-f3d7aa108e0ee39c084daf3ac3398302373169b876662a207fc116f675a5c5ca3</citedby><cites>FETCH-LOGICAL-c431t-f3d7aa108e0ee39c084daf3ac3398302373169b876662a207fc116f675a5c5ca3</cites><orcidid>0000-0002-1646-4876</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-023-06122-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-023-06122-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36717409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Nyalakonda, Ramyashree</creatorcontrib><creatorcontrib>Theruvath, Ashok J.</creatorcontrib><creatorcontrib>Sarrami, Amir Hossein</creatorcontrib><creatorcontrib>Hawk, Kristina Elizabeth</creatorcontrib><creatorcontrib>Rashidi, Ali</creatorcontrib><creatorcontrib>Shen, Sa</creatorcontrib><creatorcontrib>States, Lisa</creatorcontrib><creatorcontrib>Aboian, Mariam</creatorcontrib><creatorcontrib>Jeng, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike E.</creatorcontrib><title>Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[
18
F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH).
Methods
Twenty-three children with LCH underwent 2-[
18
F]FDG PET and WB DW-MRI at baseline. Two nuclear medicine physicians and two radiologists independently assessed presence/absence of tumors in 8 anatomical areas. Sixteen children also performed 2-[
18
F]FDG PET and WB DW-MRI at follow-up. One radiologist and one nuclear medicine physician revised follow-up scans and collected changes in tumor apparent diffusion (ADC) and standardized uptake values (SUV) before and after therapy in all detectable lesions. 2-[
18
F]FDG PET results were considered the standard of reference for tumor detection and evaluation of treatment response according to Lugano criteria. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of WB DW-MRI at baseline were calculated, and the 95% confidence intervals were estimated by using the Clopper-Pearson (exact) method; changes in tumor SUVs and ADC were compared using a Mann–Whitney
U
test. Agreement between reviewers was assessed with a Cohen’s weighted kappa coefficient. Analyses were conducted using SAS software version 9.4.
Results
Agreement between reviewers was perfect (kappa coefficient = 1) for all analyzed regions but spine and neck (kappa coefficient = 0.89 and 0.83, respectively) for 2-[
18
F]FDG PET images, and abdomen and pelvis (kappa coefficient = 0.65 and 0.88, respectively) for WB DW-MRI. Sensitivity and specificity were 95.5% and 100% for WB DW-MRI compared to 2-[
18
F]FDG PET. Pre to post-treatment changes in SUV
ratio
and ADC
mean
were inversely correlated for all lesions (
r
: -0.27,
p
= 0·06) and significantly different between responders and non-responders to chemotherapy (
p
= 0.0006 and
p
= 0·003 for SUV
ratio
and ADC
mean
, respectively).
Conclusion
Our study showed that WB DW-MRI has similar accuracy to 2-[
18
F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[
18
F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone.</description><subject>Accuracy</subject><subject>Autoimmune diseases</subject><subject>Cardiology</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Children</subject><subject>Coefficients</subject><subject>Diffusion Magnetic Resonance Imaging - methods</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Health services</subject><subject>Histiocytosis</subject><subject>Histiocytosis, Langerhans-Cell - diagnostic imaging</subject><subject>Histiocytosis, Langerhans-Cell - therapy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kappa coefficient</subject><subject>Langerhans cell histiocytosis</subject><subject>Lesions</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monitoring</subject><subject>Neoplasm Staging</subject><subject>Neoplasms</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pelvis</subject><subject>Physicians</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiation effects</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Telemedicine</subject><subject>Tumors</subject><subject>Whole Body Imaging - methods</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc9uEzEQxlcIREvhBTggS1y4GMb2xvaeEEqbtlIQCBVxQMhyvN6sq107tR2qPAGvXYct4c-B01ia33wzn7-qek7gNQEQbxIAnTUYKMPACaWYP6iOCScNFiCbh4e3gKPqSUrXAERS2TyujhgXRNTQHFc_5mHc6OhS8Ch06LYPg8Wr0O7Q6Rf8_tMlunW5RxR_JXLxbXF6jj6eXaEuRJSyXju_Rtq3KEer82h9RmPwLoe4bxQ107uhjdZPIkvt1zb22idk7DCg3qXsgtnlkFx6Wj3q9JDss_t6Un1enF3NL_Dyw_nl_N0Sm5qRjDvWCq0JSAvWssaArFvdMW0YayQrPyEY4c1KCs451RREZwjhHRczPTMzo9lJ9XbS3WxXo21NOTrqQW2iG3XcqaCd-rvjXa_W4bsiQCiRQhSFV_cKMdxsbcpqdGlvSHsbtklRIQhjdWEL-vIf9Dpsoy_-FJXAuOSsZoWiE2ViSCna7nANAbUPWk1Bq2JP_Qxa8TL04k8fh5FfyRaATUDa7OOw8ffu_8jeAQJ7tA8</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Baratto, Lucia</creator><creator>Nyalakonda, Ramyashree</creator><creator>Theruvath, Ashok J.</creator><creator>Sarrami, Amir Hossein</creator><creator>Hawk, Kristina Elizabeth</creator><creator>Rashidi, Ali</creator><creator>Shen, Sa</creator><creator>States, Lisa</creator><creator>Aboian, Mariam</creator><creator>Jeng, Michael</creator><creator>Daldrup-Link, Heike E.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1646-4876</orcidid></search><sort><creationdate>20230501</creationdate><title>Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis</title><author>Baratto, Lucia ; Nyalakonda, Ramyashree ; Theruvath, Ashok J. ; Sarrami, Amir Hossein ; Hawk, Kristina Elizabeth ; Rashidi, Ali ; Shen, Sa ; States, Lisa ; Aboian, Mariam ; Jeng, Michael ; Daldrup-Link, Heike E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-f3d7aa108e0ee39c084daf3ac3398302373169b876662a207fc116f675a5c5ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Accuracy</topic><topic>Autoimmune diseases</topic><topic>Cardiology</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Children</topic><topic>Coefficients</topic><topic>Diffusion Magnetic Resonance Imaging - methods</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Health services</topic><topic>Histiocytosis</topic><topic>Histiocytosis, Langerhans-Cell - diagnostic imaging</topic><topic>Histiocytosis, Langerhans-Cell - therapy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kappa coefficient</topic><topic>Langerhans cell histiocytosis</topic><topic>Lesions</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monitoring</topic><topic>Neoplasm Staging</topic><topic>Neoplasms</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pelvis</topic><topic>Physicians</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiation effects</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Telemedicine</topic><topic>Tumors</topic><topic>Whole Body Imaging - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Nyalakonda, Ramyashree</creatorcontrib><creatorcontrib>Theruvath, Ashok J.</creatorcontrib><creatorcontrib>Sarrami, Amir Hossein</creatorcontrib><creatorcontrib>Hawk, Kristina Elizabeth</creatorcontrib><creatorcontrib>Rashidi, Ali</creatorcontrib><creatorcontrib>Shen, Sa</creatorcontrib><creatorcontrib>States, Lisa</creatorcontrib><creatorcontrib>Aboian, Mariam</creatorcontrib><creatorcontrib>Jeng, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baratto, Lucia</au><au>Nyalakonda, Ramyashree</au><au>Theruvath, Ashok J.</au><au>Sarrami, Amir Hossein</au><au>Hawk, Kristina Elizabeth</au><au>Rashidi, Ali</au><au>Shen, Sa</au><au>States, Lisa</au><au>Aboian, Mariam</au><au>Jeng, Michael</au><au>Daldrup-Link, Heike E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>50</volume><issue>6</issue><spage>1689</spage><epage>1698</epage><pages>1689-1698</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
To assess and compare the diagnostic accuracy of whole-body (WB) DW-MRI with 2-[
18
F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis (LCH).
Methods
Twenty-three children with LCH underwent 2-[
18
F]FDG PET and WB DW-MRI at baseline. Two nuclear medicine physicians and two radiologists independently assessed presence/absence of tumors in 8 anatomical areas. Sixteen children also performed 2-[
18
F]FDG PET and WB DW-MRI at follow-up. One radiologist and one nuclear medicine physician revised follow-up scans and collected changes in tumor apparent diffusion (ADC) and standardized uptake values (SUV) before and after therapy in all detectable lesions. 2-[
18
F]FDG PET results were considered the standard of reference for tumor detection and evaluation of treatment response according to Lugano criteria. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of WB DW-MRI at baseline were calculated, and the 95% confidence intervals were estimated by using the Clopper-Pearson (exact) method; changes in tumor SUVs and ADC were compared using a Mann–Whitney
U
test. Agreement between reviewers was assessed with a Cohen’s weighted kappa coefficient. Analyses were conducted using SAS software version 9.4.
Results
Agreement between reviewers was perfect (kappa coefficient = 1) for all analyzed regions but spine and neck (kappa coefficient = 0.89 and 0.83, respectively) for 2-[
18
F]FDG PET images, and abdomen and pelvis (kappa coefficient = 0.65 and 0.88, respectively) for WB DW-MRI. Sensitivity and specificity were 95.5% and 100% for WB DW-MRI compared to 2-[
18
F]FDG PET. Pre to post-treatment changes in SUV
ratio
and ADC
mean
were inversely correlated for all lesions (
r
: -0.27,
p
= 0·06) and significantly different between responders and non-responders to chemotherapy (
p
= 0.0006 and
p
= 0·003 for SUV
ratio
and ADC
mean
, respectively).
Conclusion
Our study showed that WB DW-MRI has similar accuracy to 2-[
18
F]FDG PET for staging and treatment monitoring of LCH in children. While 2-[
18
F]FDG PET remains an approved radiological examination for assessing metabolically active disease, WB DW-MRI could be considered as an alternative approach without radiation exposure. The combination of both modalities might have advantages over either approach alone.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36717409</pmid><doi>10.1007/s00259-023-06122-6</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1646-4876</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1619-7070 |
ispartof | European journal of nuclear medicine and molecular imaging, 2023-05, Vol.50 (6), p.1689-1698 |
issn | 1619-7070 1619-7089 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10121877 |
source | MEDLINE; Springer Online Journals Complete |
subjects | Accuracy Autoimmune diseases Cardiology Chemotherapy Child Children Coefficients Diffusion Magnetic Resonance Imaging - methods Fluorine isotopes Fluorodeoxyglucose F18 Health services Histiocytosis Histiocytosis, Langerhans-Cell - diagnostic imaging Histiocytosis, Langerhans-Cell - therapy Humans Imaging Kappa coefficient Langerhans cell histiocytosis Lesions Magnetic resonance imaging Magnetic Resonance Imaging - methods Medicine Medicine & Public Health Monitoring Neoplasm Staging Neoplasms Nuclear Medicine Oncology Original Article Orthopedics Pelvis Physicians Positron emission Positron emission tomography Positron-Emission Tomography - methods Radiation effects Radiology Radiopharmaceuticals Telemedicine Tumors Whole Body Imaging - methods |
title | Comparison of whole-body DW-MRI with 2-[18F]FDG PET for staging and treatment monitoring of children with Langerhans cell histiocytosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A17%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20whole-body%20DW-MRI%20with%202-%5B18F%5DFDG%20PET%20for%20staging%20and%20treatment%20monitoring%20of%20children%20with%20Langerhans%20cell%20histiocytosis&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Baratto,%20Lucia&rft.date=2023-05-01&rft.volume=50&rft.issue=6&rft.spage=1689&rft.epage=1698&rft.pages=1689-1698&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-023-06122-6&rft_dat=%3Cproquest_pubme%3E2771334187%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2803686343&rft_id=info:pmid/36717409&rfr_iscdi=true |